News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY) Plans Big Lung Cancer Study, Pairing Immunotherapies


3/5/2014 6:26:21 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Bristol-Myers Squibb Co on Tuesday said it plans this year to begin a late-stage trial testing whether a combination of two of its high-profile immunotherapies can effectively treat lung cancer, easing concerns about the company's intentions. Company executives spooked investors in January by saying they were not yet planning a late-stage trial that would combine its experimental medicine, nivolumab, and an approved melanoma treatment called Yervoy as a treatment for lung cancer. The company's cautious timetable suggested to some investors a possible lack of "synergy" between the two drugs when targeting lung cancer.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release
Read at Reuters
Read at Market Watch
Read at Wall Street Journal

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES